GLPwatch

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

NCT03611582 · Completed

Last updated 2026-05-28

This study is testing whether the medication semaglutide, combined with an intensive lifestyle program, helps reduce body weight in adults who are overweight or have obesity.

Status Completed The study has finished.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 611 people
Who can join Ages 18+ · all sexes
Timeline Started 2018-08 · est. completion 2020-04
Where 41 sites · United States

What this study is testing ClinicalTrials.gov NCT03611582 ↗

Description as written by the study sponsor.

This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. Together with the medicine, the participant will also be part of an intensive lifestyle program where the participant will have talks with study staff about healthy food choices, what the participant can do to lose weight and be more physically active. The participant will either get semaglutide or "dummy" medicine - which treatment the participant gets is decided by chance. The participant will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. For the first 2 months the participant will be on a low calorie diet. The diet is made up of bars, shakes and 1 low calorie pre-prepared meal for each day. The study will last for about 1.5 years. The participant will have 32 clinic visits with the study doctor.

Treatments tested

Main thing measuredChange in Body Weight (%)
SponsorNovo Nordisk A/S
Conditions studiedOverweight, Obesity
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03611582 ↗